Podcasts about senate finance committee

Ben Black, Donald Trump's appointee to lead the U.S. International Development Finance Corporation, is facing scrutiny after released DOJ Epstein records showed personal and business connections between him, his family, and Jeffrey Epstein. The records reviewed by the Guardian show that Black and family members invested in Environmental Solutions Worldwide in 2011, a company where Epstein held a stake through his Virgin Islands entity, Financial Trust. Ben Black and his brother Joshua became directors of the company that same year, while Epstein's involvement intersected with Leon Black, Ben's father and Epstein's highest-paying known client. The Guardian also reported records suggesting Epstein was scheduled to meet Ben Black, obtained his contact information after a family estate-planning meeting, claimed to have attended Ben Black's 30th birthday, weighed in on Ben's $11.5 million townhouse purchase, and appeared in correspondence involving a woman who sought Epstein's advice about communicating with Ben. Black has not been accused of wrongdoing, and his spokesperson denied that he had any personal or professional relationship with Epstein.The controversy matters because Black now oversees the DFC, a taxpayer-backed overseas investment agency whose lending cap was recently tripled to $205 billion, dramatically increasing the power of the office he runs. Trump appointed Black after Black and Palantir co-founder Joe Lonsdale promoted a more market-driven approach to foreign aid, but the Guardian reported that some DFC staff had already questioned his qualifications before the Epstein records became an internal concern. The broader issue is not just whether Ben Black personally did anything improper; it is that another person placed in a high-level federal role sits inside the sprawling overlap of Epstein, elite finance, inherited power, private investment, and political appointment. The reporting also places Ben Black's rise against the backdrop of Leon Black's long financial relationship with Epstein, including the Senate Finance Committee's finding that Leon Black paid Epstein $170 million for what Black described as legitimate tax and estate-planning services.to contact me:bobbycapuccI@protonmail.comsource:Trump appointee leading $205bn US agency had personal ties to Epstein, emails show | Trump administration | The Guardian

Ben Black, Donald Trump's appointee to lead the U.S. International Development Finance Corporation, is facing scrutiny after released DOJ Epstein records showed personal and business connections between him, his family, and Jeffrey Epstein. The records reviewed by the Guardian show that Black and family members invested in Environmental Solutions Worldwide in 2011, a company where Epstein held a stake through his Virgin Islands entity, Financial Trust. Ben Black and his brother Joshua became directors of the company that same year, while Epstein's involvement intersected with Leon Black, Ben's father and Epstein's highest-paying known client. The Guardian also reported records suggesting Epstein was scheduled to meet Ben Black, obtained his contact information after a family estate-planning meeting, claimed to have attended Ben Black's 30th birthday, weighed in on Ben's $11.5 million townhouse purchase, and appeared in correspondence involving a woman who sought Epstein's advice about communicating with Ben. Black has not been accused of wrongdoing, and his spokesperson denied that he had any personal or professional relationship with Epstein.The controversy matters because Black now oversees the DFC, a taxpayer-backed overseas investment agency whose lending cap was recently tripled to $205 billion, dramatically increasing the power of the office he runs. Trump appointed Black after Black and Palantir co-founder Joe Lonsdale promoted a more market-driven approach to foreign aid, but the Guardian reported that some DFC staff had already questioned his qualifications before the Epstein records became an internal concern. The broader issue is not just whether Ben Black personally did anything improper; it is that another person placed in a high-level federal role sits inside the sprawling overlap of Epstein, elite finance, inherited power, private investment, and political appointment. The reporting also places Ben Black's rise against the backdrop of Leon Black's long financial relationship with Epstein, including the Senate Finance Committee's finding that Leon Black paid Epstein $170 million for what Black described as legitimate tax and estate-planning services.to contact me:bobbycapuccI@protonmail.comsource:Trump appointee leading $205bn US agency had personal ties to Epstein, emails show | Trump administration | The Guardian

Ben Black, Donald Trump's appointee to lead the U.S. International Development Finance Corporation, is facing scrutiny after released DOJ Epstein records showed personal and business connections between him, his family, and Jeffrey Epstein. The records reviewed by the Guardian show that Black and family members invested in Environmental Solutions Worldwide in 2011, a company where Epstein held a stake through his Virgin Islands entity, Financial Trust. Ben Black and his brother Joshua became directors of the company that same year, while Epstein's involvement intersected with Leon Black, Ben's father and Epstein's highest-paying known client. The Guardian also reported records suggesting Epstein was scheduled to meet Ben Black, obtained his contact information after a family estate-planning meeting, claimed to have attended Ben Black's 30th birthday, weighed in on Ben's $11.5 million townhouse purchase, and appeared in correspondence involving a woman who sought Epstein's advice about communicating with Ben. Black has not been accused of wrongdoing, and his spokesperson denied that he had any personal or professional relationship with Epstein.The controversy matters because Black now oversees the DFC, a taxpayer-backed overseas investment agency whose lending cap was recently tripled to $205 billion, dramatically increasing the power of the office he runs. Trump appointed Black after Black and Palantir co-founder Joe Lonsdale promoted a more market-driven approach to foreign aid, but the Guardian reported that some DFC staff had already questioned his qualifications before the Epstein records became an internal concern. The broader issue is not just whether Ben Black personally did anything improper; it is that another person placed in a high-level federal role sits inside the sprawling overlap of Epstein, elite finance, inherited power, private investment, and political appointment. The reporting also places Ben Black's rise against the backdrop of Leon Black's long financial relationship with Epstein, including the Senate Finance Committee's finding that Leon Black paid Epstein $170 million for what Black described as legitimate tax and estate-planning services.to contact me:bobbycapuccI@protonmail.comsource:Trump appointee leading $205bn US agency had personal ties to Epstein, emails show | Trump administration | The GuardianBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-moscow-murders-and-more--5852883/support.

Ben Black, Donald Trump's appointee to lead the U.S. International Development Finance Corporation, is facing scrutiny after released DOJ Epstein records showed personal and business connections between him, his family, and Jeffrey Epstein. The records reviewed by the Guardian show that Black and family members invested in Environmental Solutions Worldwide in 2011, a company where Epstein held a stake through his Virgin Islands entity, Financial Trust. Ben Black and his brother Joshua became directors of the company that same year, while Epstein's involvement intersected with Leon Black, Ben's father and Epstein's highest-paying known client. The Guardian also reported records suggesting Epstein was scheduled to meet Ben Black, obtained his contact information after a family estate-planning meeting, claimed to have attended Ben Black's 30th birthday, weighed in on Ben's $11.5 million townhouse purchase, and appeared in correspondence involving a woman who sought Epstein's advice about communicating with Ben. Black has not been accused of wrongdoing, and his spokesperson denied that he had any personal or professional relationship with Epstein.The controversy matters because Black now oversees the DFC, a taxpayer-backed overseas investment agency whose lending cap was recently tripled to $205 billion, dramatically increasing the power of the office he runs. Trump appointed Black after Black and Palantir co-founder Joe Lonsdale promoted a more market-driven approach to foreign aid, but the Guardian reported that some DFC staff had already questioned his qualifications before the Epstein records became an internal concern. The broader issue is not just whether Ben Black personally did anything improper; it is that another person placed in a high-level federal role sits inside the sprawling overlap of Epstein, elite finance, inherited power, private investment, and political appointment. The reporting also places Ben Black's rise against the backdrop of Leon Black's long financial relationship with Epstein, including the Senate Finance Committee's finding that Leon Black paid Epstein $170 million for what Black described as legitimate tax and estate-planning services.to contact me:bobbycapuccI@protonmail.comsource:Trump appointee leading $205bn US agency had personal ties to Epstein, emails show | Trump administration | The GuardianBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-moscow-murders-and-more--5852883/support.

Treasury Secretary Scott Bessent opened a Senate Finance Committee hearing by going directly after Sen. Ron Wyden, accusing him of attacking the Treasury Department over Epstein-related financial records while ignoring his own son's past contact with Jeffrey Epstein. Bessent pointed to Adam Wyden's 2016 meeting at Epstein's Manhattan mansion, where Wyden reportedly sought backing for his hedge fund, and referenced an email included in released DOJ files. The confrontation came as Wyden has continued pressing Treasury over Epstein's suspicious financial activity reports and broader money trail, arguing that the department is withholding material that could shed light on Epstein's network.Treasury Secretary Scott Bessent opened a Senate Finance Committee hearing by going directly after Sen. Ron Wyden, accusing him of attacking the Treasury Department over Epstein-related financial records while ignoring his own son's past contact with Jeffrey Epstein. Bessent pointed to Adam Wyden's 2016 meeting at Epstein's Manhattan mansion, where Wyden reportedly sought backing for his hedge fund, and referenced an email included in released DOJ files. The confrontation came as Wyden has continued pressing Treasury over Epstein's suspicious financial activity reports and broader money trail, arguing that the department is withholding material that could shed light on Epstein's network.to contact me:bobbycapucci@protonmail.comsourceScott Bessent goes scorched earth against Sen. Ron Wyden over Epstein claims

Ben Black, Donald Trump's appointee to lead the U.S. International Development Finance Corporation, is facing scrutiny after released DOJ Epstein records showed personal and business connections between him, his family, and Jeffrey Epstein. The records reviewed by the Guardian show that Black and family members invested in Environmental Solutions Worldwide in 2011, a company where Epstein held a stake through his Virgin Islands entity, Financial Trust. Ben Black and his brother Joshua became directors of the company that same year, while Epstein's involvement intersected with Leon Black, Ben's father and Epstein's highest-paying known client. The Guardian also reported records suggesting Epstein was scheduled to meet Ben Black, obtained his contact information after a family estate-planning meeting, claimed to have attended Ben Black's 30th birthday, weighed in on Ben's $11.5 million townhouse purchase, and appeared in correspondence involving a woman who sought Epstein's advice about communicating with Ben. Black has not been accused of wrongdoing, and his spokesperson denied that he had any personal or professional relationship with Epstein.The controversy matters because Black now oversees the DFC, a taxpayer-backed overseas investment agency whose lending cap was recently tripled to $205 billion, dramatically increasing the power of the office he runs. Trump appointed Black after Black and Palantir co-founder Joe Lonsdale promoted a more market-driven approach to foreign aid, but the Guardian reported that some DFC staff had already questioned his qualifications before the Epstein records became an internal concern. The broader issue is not just whether Ben Black personally did anything improper; it is that another person placed in a high-level federal role sits inside the sprawling overlap of Epstein, elite finance, inherited power, private investment, and political appointment. The reporting also places Ben Black's rise against the backdrop of Leon Black's long financial relationship with Epstein, including the Senate Finance Committee's finding that Leon Black paid Epstein $170 million for what Black described as legitimate tax and estate-planning services.to contact me:bobbycapuccI@protonmail.comsource:Trump appointee leading $205bn US agency had personal ties to Epstein, emails show | Trump administration | The GuardianBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

Ben Black, Donald Trump's appointee to lead the U.S. International Development Finance Corporation, is facing scrutiny after released DOJ Epstein records showed personal and business connections between him, his family, and Jeffrey Epstein. The records reviewed by the Guardian show that Black and family members invested in Environmental Solutions Worldwide in 2011, a company where Epstein held a stake through his Virgin Islands entity, Financial Trust. Ben Black and his brother Joshua became directors of the company that same year, while Epstein's involvement intersected with Leon Black, Ben's father and Epstein's highest-paying known client. The Guardian also reported records suggesting Epstein was scheduled to meet Ben Black, obtained his contact information after a family estate-planning meeting, claimed to have attended Ben Black's 30th birthday, weighed in on Ben's $11.5 million townhouse purchase, and appeared in correspondence involving a woman who sought Epstein's advice about communicating with Ben. Black has not been accused of wrongdoing, and his spokesperson denied that he had any personal or professional relationship with Epstein.The controversy matters because Black now oversees the DFC, a taxpayer-backed overseas investment agency whose lending cap was recently tripled to $205 billion, dramatically increasing the power of the office he runs. Trump appointed Black after Black and Palantir co-founder Joe Lonsdale promoted a more market-driven approach to foreign aid, but the Guardian reported that some DFC staff had already questioned his qualifications before the Epstein records became an internal concern. The broader issue is not just whether Ben Black personally did anything improper; it is that another person placed in a high-level federal role sits inside the sprawling overlap of Epstein, elite finance, inherited power, private investment, and political appointment. The reporting also places Ben Black's rise against the backdrop of Leon Black's long financial relationship with Epstein, including the Senate Finance Committee's finding that Leon Black paid Epstein $170 million for what Black described as legitimate tax and estate-planning services.to contact me:bobbycapuccI@protonmail.comsource:Trump appointee leading $205bn US agency had personal ties to Epstein, emails show | Trump administration | The GuardianBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

Treasury Secretary Scott Bessent opened a Senate Finance Committee hearing by going directly after Sen. Ron Wyden, accusing him of attacking the Treasury Department over Epstein-related financial records while ignoring his own son's past contact with Jeffrey Epstein. Bessent pointed to Adam Wyden's 2016 meeting at Epstein's Manhattan mansion, where Wyden reportedly sought backing for his hedge fund, and referenced an email included in released DOJ files. The confrontation came as Wyden has continued pressing Treasury over Epstein's suspicious financial activity reports and broader money trail, arguing that the department is withholding material that could shed light on Epstein's network.Treasury Secretary Scott Bessent opened a Senate Finance Committee hearing by going directly after Sen. Ron Wyden, accusing him of attacking the Treasury Department over Epstein-related financial records while ignoring his own son's past contact with Jeffrey Epstein. Bessent pointed to Adam Wyden's 2016 meeting at Epstein's Manhattan mansion, where Wyden reportedly sought backing for his hedge fund, and referenced an email included in released DOJ files. The confrontation came as Wyden has continued pressing Treasury over Epstein's suspicious financial activity reports and broader money trail, arguing that the department is withholding material that could shed light on Epstein's network.to contact me:bobbycapucci@protonmail.comsourceScott Bessent goes scorched earth against Sen. Ron Wyden over Epstein claimsBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-moscow-murders-and-more--5852883/support.

Treasury Secretary Scott Bessent opened a Senate Finance Committee hearing by going directly after Sen. Ron Wyden, accusing him of attacking the Treasury Department over Epstein-related financial records while ignoring his own son's past contact with Jeffrey Epstein. Bessent pointed to Adam Wyden's 2016 meeting at Epstein's Manhattan mansion, where Wyden reportedly sought backing for his hedge fund, and referenced an email included in released DOJ files. The confrontation came as Wyden has continued pressing Treasury over Epstein's suspicious financial activity reports and broader money trail, arguing that the department is withholding material that could shed light on Epstein's network.Treasury Secretary Scott Bessent opened a Senate Finance Committee hearing by going directly after Sen. Ron Wyden, accusing him of attacking the Treasury Department over Epstein-related financial records while ignoring his own son's past contact with Jeffrey Epstein. Bessent pointed to Adam Wyden's 2016 meeting at Epstein's Manhattan mansion, where Wyden reportedly sought backing for his hedge fund, and referenced an email included in released DOJ files. The confrontation came as Wyden has continued pressing Treasury over Epstein's suspicious financial activity reports and broader money trail, arguing that the department is withholding material that could shed light on Epstein's network.to contact me:bobbycapucci@protonmail.comsourceScott Bessent goes scorched earth against Sen. Ron Wyden over Epstein claimsBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

On Capitol Hill, Republicans are finally moving their reconciliation package forward. The Senate voted this afternoon to begin debate on the measure, which no longer includes funding for President Trump's proposed White House ballroom. The bill also comes after Acting Attorney General Todd Blanche confirmed that the administration's proposed $1.8 billion IRS "Anti-Weaponization Fund" has been dropped from the package. Democrats, however, are vowing a fight as Republicans push to advance the legislation using the reconciliation process. We'll have the latest on where the bill stands coming up. It was also a busy day of hearings on Capitol Hill. Secretary of State Marco Rubio faced questions from lawmakers on Iran and U.S. foreign policy before the House Foreign Affairs Committee. Treasury Secretary Scott Bessent defended the administration's settlement with the IRS during a Senate Finance Committee hearing. And Homeland Security Secretary Markwayne Mullin told lawmakers he is reviewing contracts signed during the tenure of former Homeland Security Secretary Kristi Noem. Plus, Campaign 2026 enters a new phase following primary elections in seven states. We'll look at the results and hear what candidates had to say in several closely watched races, including contests in California and Iowa. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us Fan MailEpisode 445 — Bob Dole: The Life That Brought Him There (Part 26)The 1981 Tax Bill, TEFRA, and Ronald ReaganIn Episode 445 of our continuing series on the life and career of Bob Dole, we examine one of the most consequential policy chapters of the early 1980s — and one that placed Dole at the center of economic policymaking in Washington.This episode focuses on two landmark pieces of legislation:• The sweeping 1981 tax cuts championed by Ronald Reagan — a cornerstone of the Reagan economic program that aimed to stimulate growth and reshape the federal tax system • And the follow-up legislation, the Tax Equity and Fiscal Responsibility Act of 1982 (TEFRA), designed to close loopholes and address the fiscal challenges that emerged in the wake of those cutsAs Chairman of the Senate Finance Committee, Bob Dole played a critical and often underappreciated role in navigating both efforts — balancing ideological goals with the practical realities of governing.This episode explores:• How the 1981 tax bill was crafted and passed • The economic and political consequences that followed • Why TEFRA became necessary just one year later • The tension between tax reduction and fiscal responsibility • The working relationship between Dole and President Reagan — cooperation, negotiation, and occasional frictionAt the heart of the story is a fundamental question: how do you govern when policy goals collide with fiscal reality?Through these debates, we see Bob Dole not just as a political figure, but as a legislative strategist — working within the system to make ambitious policy function in the real world.From bold tax cuts… to difficult corrections… and a partnership that helped define an era.This is the story of policy, power, and pragmatism in the early Reagan years. Questions or comments at  , Randalrgw1@aol.com ,  https://twitter.com/randal_wallace   , and http://www.randalwallace.com/Please Leave us a review at wherever you get your podcastsThanks for listening!!

Send us Fan MailEpisode 444 — Bob Dole: The Life That Brought Him There (Part 25)Mr. Chairman!! The Finance Committee ChairIn Episode 444 of our continuing series on the life and career of Bob Dole, we arrive at a defining moment in his rise to power in the United States Senate — his elevation to Chairman of the powerful Senate Finance Committee.For years, that gavel had been held by Russell B. Long, one of the most influential figures in the Senate and a master of its internal workings. His tenure symbolized an era when seniority and institutional control defined leadership.But with the arrival of the Reagan era, the ground beneath Washington began to shift.As the political realignment of Ronald Reagan took hold, Bob Dole stepped into the chairmanship — marking not just a personal milestone, but a broader transition in power, policy, and direction.One moment captures it all.When the new chairman was called upon for his vote — for the first time, that chairman was Bob Dole. And in a telling, almost poetic gesture, Russell Long himself responded “aye,” acknowledging both the change in leadership and the passing of an era.In this episode, we explore:• How Dole rose to claim one of the most powerful positions in the Senate • The significance of the Finance Committee in shaping national policy • The transition from Russell Long's leadership to Dole's • What this moment revealed about the changing nature of Washington in the early 1980s • How the Reagan Revolution reshaped both policy and power inside the SenateThis is more than a change in chairmanship — it is a moment of transformation.From Long to Dole… from one era to another… and from the old Senate to a new political age. Questions or comments at  , Randalrgw1@aol.com ,  https://twitter.com/randal_wallace   , and http://www.randalwallace.com/Please Leave us a review at wherever you get your podcastsThanks for listening!!

On this Friday edition of Sid & Friends in the Morning, Sid recaps last night's Round 1 of the 2026 NFL Draft which was live from Pittsburgh, Pennsylvania last night - covering the first round picks that both the New York Jets and Giants made with their first round selections. In other news of the day, the Knicks' comeback fell short in a 109-108 loss to the Hawks in Game 3 of their first round playoff matchup - leaving the Knicks trailing the series 2-1, billionaire Ken Griffin is appalled after Mayor Zohran Mamdani spotlighted his Manhattan penthouse in a viral video announcing a new pied-à-terre tax – and the hedge fund titan signaled he might even yank a $6 billion development project in the city, Bill O'Reilly rips Bruce Springsteen for his boring far-left hypocrisy on the rockstar's North-American tour, and HHS Secretary Robert F. Kennedy Jr. testifies before the Senate Finance Committee amid brewing controversy over his vaccine policies and a measles outbreak. Blaire White, Brian Kilmeade, Joe Tacopina, K.T. McFarland, Randy Sutton, Scott LoBaido & Stephen A. Smith join Sid on this Friday installment of Sid & Friends in the Morning. Learn more about your ad choices. Visit megaphone.fm/adchoices

Health Secretary Robert F. Kennedy Jr. appeared before the Senate Finance Committee and the Senate HELP Committee Wednesday to answer questions about measles, vaccines, nutrition and budget cuts. NPR's Selena Simmons-Duffin reports.Support NPR and hear every episode of Trump's Terms sponsor-free with NPR+. Sign up at plus.npr.org.See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy

On today's Midday Report with host Terry Haines: Civil rights advocates are suing over Alaska's decision last year to share confidential voter data. The state Senate Finance Committee released its first revision of the state's operating budget YESTERDAY, including a $1,000 Permanent Fund dividend and a $150 energy relief check. The Chilkat River, in Southeast Alaska on a list of ten most endangered waterways.Photo: The Chilkat river and broader watershed, pictured above in March 2026. (Avery Ellfeldt/ KHNS)

A Susitna Valley kennel owner who was among the first to raise concerns about the welfare of dogs found dead on a Mat-Su Borough property says the community is still searching for answers even after a Willow woman was charged with dozens of felonies. A body was found in Fairbanks last week, launching an effort by authorities to track down family for the individual. The Senate Finance Committee reduced the Permanent Fund Dividend to $1,000 Wednesday in their new version of the operating budget, a cut down from the $1,500 the House passed.

Health Secretary Robert F. Kennedy Jr. testifies before the Senate Finance Committee on April 22 about the department's fiscal year 2027 budget request. It's the sixth of seven hearings on that budget plan.Virginia voters on April 21 approved a new congressional map that could boost the chances of the Democratic Party winning four additional U.S. House seats in November's midterm elections.Democrats are looking to offset GOP gains in Texas after its new map was drawn to favor the Republicans in Congress.

UCSB undergraduate students pay around 240 dollars to Associated Students every school year. Where does this money go and who is in charge of disbursing it? KCSB's Tatiana Jacquez interviewed AS Finance Committee Chair, Jenny Jiang, to learn more about financial allocations by the Finance Committee, and how their budgetary process works.

Max Baucus served for more than 35 years in the United States Senate before becoming the United States Ambassador to China. The longest-serving U.S. Senator in Montana history, Senator Baucus was the Chairman of the Senate Finance Committee - one of the most powerful positions in Congress - and played a central role in shaping the Affordable Care Act. Senator Baucus joins Adam to share his journey and his best lessons and advice. Senator Baucus and Adam discuss leadership, career success, negotiations and dealmaking, decision making, trust, and much more.

On this episode of the South Carolina Lede for April 14, 2026: we look at the Senate Finance Committee's version for the budget and hear from the state's chief economist on how healthy revenues are; we hear from SCDOT Secretary Justin Powell on a major groundbreaking for the I-95 bridge over Lake Marion; Sen. Lindsey Graham has one fewer challengers; and more!

Director of Advocacy Casey Fields and Legislative and Public Policy Advocacy Daina Riley Phillips discuss the differences between the Senate Finance Committee's version of the state budget and the House version, including the funding amounts for a road buyback program, bridge modernization and beach renourishment grants.

Lawmakers in both chambers of Congress are taking a closer look at a range of bipartisan IRS administration changes. House tax writers have advanced several pieces of legislation that would fix problems identified by taxpayer advocates and tax professionals. Some have become law. Senate Finance Committee lawmakers, meanwhile, recently introduced a large package that includes dozens of provisions that include digitizing more paper returns, providing more online information about refunds, and enhancing standards for tax return preparers. The interest in tax administration suggests there's a willingness among tax writers to try to take action—the key question is how. The two chambers' different approaches show an emerging disagreement over strategy. On this episode of Talking Tax, host David Schultz talks to Bloomberg Tax reporter Chris Cioffi about how a tax administration legislation has been taking shape, as well as the path forward in Congress. Do you have feedback on this episode of Talking Tax? Give us a call and leave a voicemail at 703-341-3690.

Solidaris Capital LLC is involved in a whistleblower complaint concerning a tax shelter strategy that allows wealthy investors to claim substantial tax deductions by donating digital technology to charities. The strategy involves investing in shell companies that acquire technology at a low cost, which is then donated to charities at a higher valuation, potentially securing deductions five times the initial investment. The legality of this approach is under scrutiny, with former IRS, SEC, and DOJ officials questioning its economic rationale. The Senate Finance Committee is reviewing the complaint, and Senator Ron Wyden has highlighted the need for clear rules on digital asset tax treatment. The strategy's potential replication raises concerns about IRS enforcement capabilities.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.

The lawsuits filed against Leon Black in connection with Jeffrey Epstein are among the most graphic and disturbing to emerge from Epstein's orbit. Several women, including Cheri Pierson and a plaintiff identified as Jane Doe, accuse Black of violent sexual assaults that allegedly took place inside Epstein's Manhattan townhouse. Pierson claims Black raped her in 2002 after Epstein arranged what was supposed to be a massage appointment, describing the encounter as brutal and coercive. Another lawsuit alleges Black sexually assaulted a 16-year-old girl with autism and Down syndrome, leaving her bleeding and traumatized. Both cases portray Black as a predator who exploited Epstein's network to target vulnerable women, echoing the broader pattern of abuse associated with Epstein's inner circle. Black's legal team has vehemently denied all allegations, dismissing the claims as false and opportunistic.Compounding the scandal is Black's series of high-dollar settlements and legal maneuvering. In 2023, he quietly paid $62.5 million to the U.S. Virgin Islands to avoid potential litigation tied to Epstein's trafficking operations there. He also succeeded in getting parts of other lawsuits dismissed on procedural grounds, including a defamation case brought by former model Guzel Ganieva, which was thrown out in early 2025. Still, the volume and nature of the claims — combined with his massive financial ties to Epstein and the Senate Finance Committee's scrutiny of his payments — have left Black mired in controversy. The lawsuits' explicit, violent allegations and the perception of systemic leniency have solidified his position as one of the most controversial figures to emerge from Epstein's shadow.to contact me:bobbycapucci@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-moscow-murders-and-more--5852883/support.

For a demo of the Behavioral Governance Special Purpose Avatar - contact Eric Dyson at edyson@90northllc.com Don Trone, GFS™, is the CEO of the Behavioral Governance Institute (BGI), where he leads the development of Special Purpose Avatars (SPAs) designed to accelerate the professional development of leaders, stewards, and fiduciaries with governance responsibility. Widely known as the “Father of Fiduciary,” he has spent decades shaping fiduciary standards and governance practices. He was the founding CEO of fi360, the Center for Board Certified Fiduciaries, and the Foundation for Fiduciary Studies, and previously directed the Institute for Leadership at the U.S. Coast Guard Academy.A former U.S. Coast Guard helicopter rescue pilot, Don brings real-world experience from high-stakes environments to his focus on clarity, foresight, and accountability in governance. He has also testified before the U.S. Senate Finance Committee and the Department of Labor on fiduciary best practices.In this episode, Eric and Don Trone discuss:The origins of the Behavioral Governance Institute and why fiduciary standards alone are not enoughHow leadership behaviors and decision-making frameworks influence retirement outcomesThe development of “Special Purpose Avatars” is designed to support governance professionalsHow AI-powered avatars can deliver personalized professional development and trainingKey Takeaways:Behavioral governance expands the traditional fiduciary framework. Instead of focusing only on procedural prudence, it integrates leadership, judgment, ethics, and decision-making into governance responsibilities.AI-powered avatars are emerging as powerful tools for professional development. By curating expert knowledge in closed systems, these avatars help professionals strengthen their understanding of complex governance and fiduciary responsibilities.The future of professional education is shifting from traditional classroom-style programs to on-demand learning experiences. AI avatars enable a “Netflix-style” training model where professionals control when, how, and what they learn.Mastery-based learning loops represent a major advancement in professional education. Instead of allowing professionals to pass certification tests with partial understanding, avatars keep users in a training loop until they demonstrate full mastery of the subject.“If we had a better understanding of how certain leadership behaviors impact the quality of decision-making outcomes, we could have a material positive impact on the management of investment decisions.” - Don TroneConnect with Don Trone:Website: https://www.3ethos.com/ LinkedIn: https://www.linkedin.com/in/don-trone-89873013/ Connect with Eric Dyson: Website: https://90northllc.com/Phone: 940-248-4800Email: contact@90northllc.com LinkedIn: https://www.linkedin.com/in/401kguy/ The information and content of this podcast are general in nature and are provided solely for educational and informational purposes. It is believed to be accurate and reliable as of the posting date, but may be subject to change.It is not intended to provide a specific recommendation for any type of product or service discussed in this presentation or to provide any warranties, investment advice, financial advice, tax, plan design, or legal advice (unless otherwise specifically indicated). Please consult your own independent advisor as to any investment, tax, or legal statements made.The specific facts and circumstances of all qualified plans can vary, and the information contained in this podcast may or may not apply to your individual circumstances or to your plan or client plan-specific circumstances.The opinions expressed by guests on the Be More Than a Fiduciary podcast are not necessarily the same as the opinions held by 90 North Consulting, or of Executive Director Eric Dyson.

In July 2023, billionaire Leon Black, co-founder of Apollo Global Management, agreed to pay roughly $62.5 million to the U.S. Virgin Islands to resolve potential claims tied to his financial dealings with Jeffrey Epstein. The USVI had been pursuing Epstein's estate and associates for enabling or benefiting from his trafficking network, and Black was facing scrutiny over large payments made to Epstein's companies for so-called “financial advice.” The settlement gave Black immunity from criminal liability in the USVI and ended the possibility of a lawsuit there, though it did not include an admission of wrongdoing. Black has consistently said the payments were legitimate professional fees and that he had no knowledge of Epstein's crimes.The deal, however, did not put all questions to rest. Around the same time, the Senate Finance Committee, led by Senator Ron Wyden, released documents showing Black paid Epstein far more than originally known—over $150 million between 2012 and 2017—sparking deeper concerns that such vast sums may have indirectly financed Epstein's operations. The revelations intensified scrutiny not only of Black's judgment but also of whether banks and institutions involved properly flagged or investigated the transactions. While the $62 million settlement resolved matters with the Virgin Islands, it left lingering doubts about the true nature of Black's relationship with Epstein and whether full accountability was ever reached.to contact me:bobbycapucci@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-moscow-murders-and-more--5852883/support.

In July 2023, billionaire Leon Black, co-founder of Apollo Global Management, agreed to pay roughly $62.5 million to the U.S. Virgin Islands to resolve potential claims tied to his financial dealings with Jeffrey Epstein. The USVI had been pursuing Epstein's estate and associates for enabling or benefiting from his trafficking network, and Black was facing scrutiny over large payments made to Epstein's companies for so-called “financial advice.” The settlement gave Black immunity from criminal liability in the USVI and ended the possibility of a lawsuit there, though it did not include an admission of wrongdoing. Black has consistently said the payments were legitimate professional fees and that he had no knowledge of Epstein's crimes.The deal, however, did not put all questions to rest. Around the same time, the Senate Finance Committee, led by Senator Ron Wyden, released documents showing Black paid Epstein far more than originally known—over $150 million between 2012 and 2017—sparking deeper concerns that such vast sums may have indirectly financed Epstein's operations. The revelations intensified scrutiny not only of Black's judgment but also of whether banks and institutions involved properly flagged or investigated the transactions. While the $62 million settlement resolved matters with the Virgin Islands, it left lingering doubts about the true nature of Black's relationship with Epstein and whether full accountability was ever reached.to contact me:bobbycapucci@protonmail.com

In July 2023, billionaire Leon Black, co-founder of Apollo Global Management, agreed to pay roughly $62.5 million to the U.S. Virgin Islands to resolve potential claims tied to his financial dealings with Jeffrey Epstein. The USVI had been pursuing Epstein's estate and associates for enabling or benefiting from his trafficking network, and Black was facing scrutiny over large payments made to Epstein's companies for so-called “financial advice.” The settlement gave Black immunity from criminal liability in the USVI and ended the possibility of a lawsuit there, though it did not include an admission of wrongdoing. Black has consistently said the payments were legitimate professional fees and that he had no knowledge of Epstein's crimes.The deal, however, did not put all questions to rest. Around the same time, the Senate Finance Committee, led by Senator Ron Wyden, released documents showing Black paid Epstein far more than originally known—over $150 million between 2012 and 2017—sparking deeper concerns that such vast sums may have indirectly financed Epstein's operations. The revelations intensified scrutiny not only of Black's judgment but also of whether banks and institutions involved properly flagged or investigated the transactions. While the $62 million settlement resolved matters with the Virgin Islands, it left lingering doubts about the true nature of Black's relationship with Epstein and whether full accountability was ever reached.to contact me:bobbycapucci@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

The Senate Finance Committee hosted a hearing on the importance of the U.S.-Mexico-Canada Agreement. Chad Smith has more.

Podcast host Lou DiVizio updates you on several big-ticket bills moving through the legislature as we approach the final gavel Thursday at noon.Then, Senate Finance Chair George Muñoz, a Gallup Democrat, talks to host Nash Jones about several contentious line items in the state's budget, including copays for universal childcare and billions set aside for public and higher education.  And, Politics correspondent Gwyneth Doland checks in with Sen. Steve Lanier, the second-ranking Republican on the Senate Finance Committee and a candidate for governor, to learn where the state GOP stands on the budget. Podcast Host: Lou DiVizioNMiF Show Host: Nash JonesCorrespondent: Gwyneth DolandGuests: NM Sen. George Muñoz, D-Gallup; Senate Finance ChairNM Sen. Steve Lanier, R-San Juan CountyFor More Information: Universal ChildcareHealthcare FundingClear Horizons ActSB 17 Gun ControlState Budget - HB 2

Headlines on today's episode include:-Senate Finance Committee holds USMCA hearing-Storage capacity at a crossroads-A look at ethanol exports-E15 supporters anxious for council movement-No-till and cereal rye improve soil fertility and farm profitability Kubota. Your compact equipment provider.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Leaders of the Senate Finance Committee want answers from the Social Security Administration about DOGE sharing its data. Chairman Mike Crapo and Ranking Member Ron Wyden are asking SSA what agency data was shared with outside groups. The Justice Department recently told a federal court that DOGE staffers at the agency discussed sharing agency data with an advocacy group looking to “overturn election results” in some states. DOJ referred the two DOGE employees for potential violations of the Hatch Act.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textBob Dole returns January 20, 2026Bob Dole: The Life That Brought Him There — Season PreviewHow does a small-town Kansas boy, gravely wounded on an Italian battlefield, rise to become one of the most powerful and respected figures in American politics?This season of Bob Dole: The Life That Brought Him There traces the extraordinary journey of Bob Dole from the moment his life was forever changed in World War II through his ascent to the highest levels of American government. Beginning with his devastating combat injury and long recovery, the series follows Dole through his early political career in Kansas, his elections to Congress and the U.S. Senate, his tenure as Republican National Committee Chairman, and his emergence as a central figure in Washington during some of the most turbulent decades in modern history.Listeners will travel with Dole through the Nixon years and Watergate, the razor-thin 1974 Senate race against Dr. Bill Roy, and his rise onto the national stage as Gerald Ford's 1976 vice-presidential running mate. The season continues through his 1980 and 1988 presidential campaigns, his pivotal role as Chairman of the Senate Finance Committee, and his leadership in landmark moments such as saving Social Security in 1983 and launching the historic McGovern–Dole effort to feed hungry children around the world.As both Senate Minority Leader and Majority Leader, Bob Dole became one of the great legislative strategists of his era, and this series reveals how power was actually wielded in Congress from the 1970s through the 1990s—how deals were made, how coalitions were built, and how policy became law.Featuring voices of friends and foes alike—fellow senators, staffers, journalists, and contemporaries—along with rare archival audio from news coverage and C-SPAN, this season offers an intimate, inside-the-room portrait of a man who helped shape a generation of American politics.More than a biography, Bob Dole: The Life That Brought Him There is a master class in leadership, resilience, and the inner workings of the United States Senate at a time when history was being written day by day.Questions or comments at , Randalrgw1@aol.com , https://twitter.com/randal_wallace , and http://www.randalwallace.com/Please Leave us a review at wherever you get your podcastsThanks for listening!!

Newt talks with Brian Blase, president of Paragon Health Institute and former special assistant to the President for Economic Policy at the White House's National Economic Council. Their discussion centers on the rising cost of healthcare in the United States, a pressing issue that Blase recently addressed before the Senate Finance Committee. Blase explains the mission of the Paragon Health Institute, which he founded to fill a void in the free market community by analyzing government healthcare programs and developing policy solutions that expand choice and market competition. Their conversation highlights significant issues such as fraud and corruption in government healthcare programs, with examples of the massive fraud in Minnesota and improper enrollments in Obamacare. Blase emphasizes the need for reform in Medicare payment policies and the importance of consumer control over healthcare financing to reduce costs. They conclude their discussion with a call for transparency in healthcare pricing.See omnystudio.com/listener for privacy information.

Senators, primarily through the U.S. Senate Finance Committee under the leadership of Sen. Ron Wyden (D-Ore.), launched a lengthy investigation beginning in 2022 into billionaire financier Leon Black's financial relationship with Jeffrey Epstein and the unusually large payments Black made to Epstein—totaling at least $158 million, and possibly as much as $170 million—between 2012 and 2017 for purported tax and estate planning advice that many lawmakers find dubious given Epstein's lack of professional credentials. The committee has pressed Black and financial institutions like Bank of America for details about how these funds were managed and why banks did not flag the massive transfers as suspicious in real time, as required under anti-money-laundering regulations. Investigators also noted that Epstein was paid far more than typical advisors and that some of the money may have been used to support Epstein's wider operations.Wyden's investigation has expanded to demand transparency from the Department of Justice, Treasury, and Internal Revenue Service, urging those agencies to release Suspicious Activity Reports (SARs) tied to Epstein's finances and to audit the tax and estate planning work Epstein performed for Black. The Senate's efforts come amid concerns that oversight has been inadequate, and include seeking documents that might show whether Black's payments helped fund Epstein's alleged criminal network. Black has publicly denied involvement in Epstein's crimes and maintains the payments were lawful, and an independent review commissioned by Black's firm found no criminal activity; nevertheless, the Senate's scrutiny continues as part of broader efforts to understand how Epstein's financial networks operated and were used, and whether existing tax and financial laws were properly enforced.to contact me:bobbycapucci@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

Dr. Monty Pal and Dr. Jason Westin discuss the federal funding climate for cancer research and the persistent problem of drug shortages, two of the major concerns facing the oncology community in 2026. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I am your host, Dr. Monty Pal. I am a medical oncologist and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. There are always multiple challenges facing oncologists, and today, we discuss two of them that really stand out for 2026: threats to federal funding for cancer research and the persistent problem of drug shortages. I am thrilled to welcome Dr. Jason Westin, who believes that one way to meet these challenges is to get oncologists more involved in advocacy, and he will share some strategies to help us meet this moment in oncology. Dr. Westin is a professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, but he actually wears a lot of hats within ASCO. He is a member of the Board of Directors and has also previously served as chair of ASCO's Government Relations Committee. And he is also one of the inaugural members of ASCO's Political Action Committee, or PAC. He has testified before Congress about drug shortages and many other issues. Dr. Westin, I am really excited to have you on the podcast today and dive into some of these elements that will really impact our community in 2026. Thanks so much for joining us today. Dr. Jason Westin: Thank you for having me. Dr. Monty Pal: You've had such a range of experience. I already alluded to you testifying before Congress. You've actually run for office before. You wear so many different hats. I'm used to checking my PubMed every other day and seeing a new paper out from you and your group, and you publish in the New England Journal [of Medicine] on practice-setting standards and the diseases that you treat. But you've also done all this work in the domain of advocacy. I can't imagine that balancing that is easy. What has sort of motivated you on the advocacy front? Dr. Jason Westin: Advocacy to me is another way to apply our skills and help more people than just those that you're sitting across from at the time. Clinical research, of course, is a tool to try and take what we know and apply it more broadly to people that you'll never meet. And advocacy, I think, can do the same thing, where you can have a conversation with a lawmaker, you can advocate for a position, and that hopefully will help thousands or maybe even more people down the road who you'd never get to directly interact with. And so, I think it's a force multiplier in the same way that research can be. And so, I think advocacy is a wonderful part of how doctors care for our patients. And it's something that is often difficult to know where to start, but once people get into advocacy, they can see that the power, the rewarding nature of it is attractive, and most people, once they get going, continue with that through the rest of their career. Dr. Monty Pal: So, I'll ask you to expand on that a little bit. We have a lot of our younger ASCO members listening to this podcast, folks that are just starting out their careers in clinical practice or academia. Where does that journey begin? How do you get to the point that you're testifying in front of Congress and taking on these bigger sort of stances for the oncology community? Dr. Jason Westin: Yeah, with anything in medicine and in our careers, you have to start somewhere. And often you start with baby steps before you get in front of a panel of senators or other high-profile engagement opportunities. But often the first setting for junior colleagues to be engaged is doing things – we call them "Hill Days" – but basically being involved in kind of low-stakes meetings where you're with a group of peers, some of whom have done this multiple times before, and can get engaged talking to members of representatives' offices, and doing so in a way where it's a natural conversation that you're telling a story about a patient in your clinic, or that you're telling a personal experience from a policy that impacted your ability to deliver optimal care. It sounds stressful, but once you're doing it, it's not stressful. It's actually kind of fun. And it's a way that you can get comfort and skill with a group of peers who are there and able to help you. And ASCO has a number of ways to do that, both at the federal level, there's the Hill Day where we each April have several hundred ASCO members travel to Capitol Hill. There's also state engagement that can be done, so-called visiting at home, when representatives from the U.S. Congress or from state legislators are back in district. You can meet with your own representatives on behalf of yourself, on behalf of your organization, and advocate for policies in a way that can be beneficial to your patients. But those initial meetings that are in the office often they're low stakes because you could be meeting not with the representative but with their staff. And that staff sometimes is as young or even younger than our junior colleagues. These sometimes can be people in their 20s, but they're often extremely knowledgeable, extremely approachable, and are used to dealing with people who are new to advocacy. But they actually help make decisions within the office. So it's not a waste of time. It's actually a super useful way to engage. So, it's that first step of anything in life. The activation energy is always high to do something new. But I'd encourage people who are listening to this podcast already having some level of interest about it to explore ways that they could engage more. Dr. Monty Pal: You know, I have to tell you, I'm going to riff on what you just said for a second. ASCO couldn't make it any easier, I think, for folks to participate and get involved. So, if you're listening to this and scratching your head and thinking, "Well, where do I begin? How do I actually sign on for that meeting with a local representative?" Go to the ASCO ACT Network website. And I'll actually talk to our producer, Geraldine, to make sure we've got a link to that somewhere associated with this podcast after it's published, Jason, but I actually keep that on my browser and it's super easy. I check in there every now and then and see if there's any new policy or legislation that ASCO, you know, is sort of taking a stance on, and it gives me some fodder for conversation with my local representatives too. I mean, it's just an awesome, awesome vehicle. I'm going to segue right from there right to the issues. So, you and I are both at academic centers. You know, I think this is something that really pervades academia and enters into implications for general clinical practice. There's been this, you know, massive sort of proposal for decreased funding to the NCI and to the NIH and so forth. Tell us what ASCO is doing in that regard, and tell us perhaps how our community can help. Dr. Jason Westin: We live in interesting times, and I think that may be an understatement x 100. But obviously investments in research are things that when you're at an academic center, you see and feel that as part of your daily life. Members of Congress need to be reminded of that because there's a lot of other competing interests out there besides investing in the future through research. And being an elected representative is a hard job. That is something where you have to make difficult choices to support this, and that may mean not supporting that. And there's lots of good things where our tax dollars could be spent. And so, I'm sympathetic to the idea that there's not unlimited resources. However, ASCO has done an excellent job, and ASCO members have led the charge on this, of stating what research does, what is the benefit of research, and therefore why should this matter to elected representatives, to their staff, and to those people that they're elected to serve. And ASCO has led with a targeted campaign to basically have that message be conveyed at every opportunity to elected representatives. And each year on Hill Day, one of the asks that we have is to continue to support research: the NCI, NIH, ARPA-H, these are things that are always in the asks to make sure that there's appropriate funding. But effectively playing offense by saying, "It's not just a number on a sheet of paper, this is what it means to patients. This is what it means to potentially your loved ones in the future if you are in the opposite situation where you're not on the legislative side, but you're in the office receiving a diagnosis or receiving a difficult piece of news." We only have the tools we have now because of research, and each breakthrough has been years in the making and countless hours spent funded through the engine of innovation: clinical research and translational research. And so ASCO continues to beat that drum. You mentioned earlier the ACT Network. Just to bring that back again is a very useful, very easy tool to communicate to your elected representatives. When you sign up on the ASCO ACT website, you get emails periodically, not too much, but periodically get emails of, "This is a way you can engage with your lawmakers to speak up for this." And as you said, Monty, they make it as easy as possible. You click the button, you type in your address so that it figures out who your elected representatives are, and then it will send a letter on your behalf after like five clicks to say, "I want you to support research. I want you to vote for this particular thing which is of interest to ASCO and by definition to members of ASCO." And so the ACT Network is a way that people listening can engage without having to spend hours and significant time, but just a few clicks can send that letter to a representative in Congress. And the question could be: does that matter? Does contacting your senator or your elected representative do anything? If all they're hearing is somebody else making a different argument and they're hearing over and over again from people that want investments in AI or investments in something else besides cancer research, whatever it is, they may think that there's a ground shift that people want dollars to be spent over here as opposed to at the NIH or NCI or in federally funded research. It is important to continue to express the need for federal funding for our research. And so, it really is important for folks to engage. Dr. Monty Pal: 100%. One of the things that I think is not often obvious to a lot of our listeners is where the support for clinical trials comes from. You know, you've obviously run the whole gamut of studies as have I. You know, we have our pharmaceutical company-sponsored studies, which are in a particular bucket. But I would say that there's a very important and critical subset of studies that are actually government funded, right? NCI-funded clinical trials. If you don't mind, just explain to our audience the critical nature of the work that's being done in those types of studies and if you can, maybe compare and contrast the studies that are done in that bucket versus perhaps the pharmaceutical bucket. Dr. Jason Westin: Both are critical, and we're privileged that we have pharma studies that are sponsored and federally funded clinical research. And I think that part of a healthy ecosystem for us to develop new breakthroughs has a need for both. The pharma sponsored studies are done through the lens of trying to get an approval for an agent that's of interest so that the pharma company can then turn around and use that outside of a clinical trial after an FDA approval. And so those studies are often done through the lens of getting over the finish line by showing some superiority over an existing treatment or in a new patient population. But they're done through that lens of kind of the broadest population and sometimes relatively narrow endpoints, but to get the approval so that then the drug can be widely utilized. Clinical trials done through cooperative groups are sometimes done to try and optimize that or to try and look at comparative things that may not be as attractive to pharma studies, not necessarily going for that initial approval, but the fine tuning or the looking at health outcomes or looking at ensuring that we do studies in representative populations that may not be as well identified on the pharma sponsored trials, but basically filling out the gaps in the knowledge that we didn't gain from the initial phase 3 trial that led to the approval. And so both are critical. But if we only do pharma sponsored trials, if we don't fund federally supported research and that dries up, the fear I have, and many others have, is that we're going to be lacking a lot of knowledge about the best ways to use these great new therapies, these new immune therapies, or in my team, we do a lot of clinical trials on CAR T-cell therapies. If we don't have federally funded research to do the important clinical studies, we'll be in the dark about the best ways to use these drugs, and that's going to be a terrible shame. And so we really do need to continue to support federal research. Dr. Monty Pal: Yeah, there are no softball questions on this podcast, but I think everybody would be hard pressed to think that you and I would come on here and say, "Well, no, we don't need as much money for clinical trials and NCI funding" and so forth. But I think a really challenging issue to tackle, and this is something we thought to ask you ahead of the podcast, is what to do about the general climate of, you know, whether it's academic research or clinical practice here that seems to be getting some of our colleagues thinking about moving elsewhere. I've actually talked to a couple of folks who are picking up and moving to Europe for a variety of considerations, other continents, frankly. The U.S. has always been a leader when it comes to oncology research and, one might argue, research in general. Some have the mindset these days that we're losing that footing a little bit. What's your perspective? Are you concerned about some of the trends that you're seeing? What does your crystal ball tell you? Dr. Jason Westin: I am highly concerned about this. I think as you said, the U.S. has been a leader for a long time, but it wasn't always. This is not something that's preordained that the world-leading clinical research and translational research will always be done in the United States. That is something that has been developed as an ecosystem, as an engine for innovation and for job development, new technology development, since World War II. That's something that through intentional investments in research was developed that the best and brightest around the world, if they could choose to go anywhere, you wanted them to come to work at universities and academic places within the United States. And I think, as you said, that's at risk if you begin to dry up the investment in research or if you begin to have less focus on being engaged in research in a way that is forward thinking, not just kind of maintaining what we do now or only looking at having private, for profit sponsored research. But if you don't have the investment in the basic science research and the translational research and the forward-thinking part of it, the fear is that we lose the advantage and that other countries will say, "Thank you very much," and be happy to invest in ways to their advantage. And I think as you mentioned, there are people that are beginning to look elsewhere. I don't think that it's likely that a significant population of researchers in the U.S. who are established and have careers and families – I don't think that we're going to see a mass exodus of folks. I think the real risk to me is that the younger, up-and-coming people in undergraduate or in graduate school or in medical school and are the future superstars, that they could either choose to go into a different field, so they decide not to go into what could be the latest breakthroughs for cancer patients but could be doing something in AI or something in a different field that could be attractive to them because of less uncertainty about funding streams, or they could take that job offer if it's in a different country. And I think that's the concern is it may not be a 2026 problem, but it could be a 2036 or a 2046 problem that we reap what we sow if we don't invest in the future. Dr. Monty Pal: Indeed, indeed. You know, I've had the pleasure of reviewing abstracts for some of our big international meetings, as I'm sure you've done in the past too. I see this trend where, as before, we would see the preponderance of large phase 3 clinical trials and practice setting studies being done here in the U.S., I'm seeing this emergence of China, of other countries outside of the U.S. really taking lead on these things. And it certainly concerns me. If I had to sort of gauge this particular issue, it's at the top of my list in terms of what I'm concerned about. But I also wanted to ask you, Jason, in terms of the issues that are looming over oncology from an advocacy perspective, what else really sort of keeps you up at night? Dr. Jason Westin: I'm quite concerned about the drug shortages. I think that's something that is a surprisingly evergreen problem. This is something that is on its face illogical that we're talking about the greatest engine for research in the world being the United States and the investment that we've made in drug development and the breakthroughs that have happened for patients all around the world, many of them happen in the United States, and yet we don't necessarily have access to drugs from the 1970s or 1980s that are cheap, generic, sterile, injectable drugs. This is the cisplatins and the vincristines and the fludarabine type medications which are not the sexy ones that you see the ads in the magazine or on TV at night. These are the backbone drugs for many of our curative intent regimens for pediatrics and for heme malignancies and many solid tumors. And the fact that that's continuing to be an issue is, in my opinion, a failure to address the root causes, and those are going to require legislative solutions. The root causes here are basically a race to the bottom where the economics to invest in quality manufacturing really haven't been prioritized. And so it's a race to the cheapest price, which often means you undercut your competitor, and when you don't have the money to invest in good manufacturing processes, the factory breaks down, there's no alternative, you go into shortage. And this has been going on for a couple of decades, and I don't think there's an end in sight until we get a serious solution proposed by our elected officials. That is something that bothers me in the ways where we know what we should be doing for our patients, but if we don't have the drugs, we're left to be creative in ways we shouldn't have to do to figure out a plan B when we've got curative intent therapies. And I think that's a real shame.  There's obviously a lot of other things that are concerning related to oncology, but something that I have personally had experience with when I wanted to give a patient a CAR T-cell, and we don't have a supply of fludarabine, which is a trivial drug from decades ago in terms of the technology investments in genetically modified T-cells, to not then have access to a drug that should be pennies on the dollar and available at any time you want it is almost like the Air Force investing in building the latest stealth bomber, but then forgetting to get the jet fuel in a way that they can't use it because they don't have the tools that they need. And so I think that's something that we do need to have comprehensive solutions from our elected officials. Dr. Monty Pal: Brilliantly stated. I like that analogy a lot. Let's get into the weeds for a second. What would that proposal to Congress look like? What are we trying to put in front of them to help alleviate the drug shortages? Dr. Jason Westin: We could spend a couple hours, and I know podcasts usually are not set up to do that. And so I won't go through every part. I will direct you that there have been a couple of recent publications from ASCO specifically detailing solutions, and there was a recent white paper from the Senate Finance Committee that went through some legislative solutions being explored. So Dr. Gralow, ASCO CMO, and I recently had a publication in JCO OP detailing some solutions, more in that white paper from the Senate Finance. And then there's a working group actually going through ASCO's Health Policy Committee putting together a more detailed proposal that will be published probably around the end of 2026. Very briefly, what needs to happen is for government contracts for purchasing these drugs, there needs to be an outlay for quality, meaning that if you have a manufacturing facility that is able to deliver product on time, reliably, you get a bonus in terms of your contract. And that changes the model to prioritize the quality component of manufacturing. Without that, there's no reason to invest in maintaining your machine or upgrading the technology you have in your manufacturing plant. And so you have bottlenecks emerge because these drugs are cheap, and there's not a profit margin. So you get one factory that makes this key drug, and if that factory hasn't had an upgrade in their machines in 20 years, and that machine conks out and it takes 6 months to repair or replacement, that is an opportunity for that drug to go into shortage and causes a mad dash for big hospitals to purchase the drug that's available, leaving disparities to get amplified. It's a nightmare when those things happen, and they happen all the time. There are usually dozens, if not hundreds, of drugs in shortage at any given time. And this has been going on for decades. This is something that we do need large, system-wide fixes and that investment in quality, I think, will be a key part. Dr. Monty Pal: Yeah, brilliantly said. And I'll make sure that we actually include those articles on the tagline for this podcast as well. I'll talk to our producer about that as well.  I'm really glad you mentioned the time in your last comment there because I felt like we just started, but in fact, I think we're right at our close here, Jason, unfortunately. So, I could have gone on for a couple more hours with you. I really want to thank you for these absolutely terrific insights and thank you for all your advocacy on behalf of ASCO and oncologists at large. Dr. Jason Westin: Thank you so much for having me. I have enjoyed it. Dr. Monty Pal: Thanks a lot. And many thanks to our listeners too. You can find more information about ASCO's advocacy agenda and activities at asco.org. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks so much. ASCO Advocacy Resources: Get involved in ASCO's Advocacy efforts: ASCO Advocacy Toolkit Crisis of Cancer Drug Shortages: Understanding the Causes and Proposing Sustainable Solutions, JCO Oncology Practice Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:     Dr. Monty Pal   @montypal   Dr. Jason Westin @DrJasonWestin   Follow ASCO on social media:      @ASCO on X     ASCO on Bluesky    ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Jason Westin: Consulting or Advisory Role: Novartis, Kite/Gilead, Janssen Scientific Affairs, ADC Therapeutics, Bristol-Myers Squibb/Celgene/Juno, AstraZeneca, Genentech/Roche, Abbvie, MorphoSys/Incyte, Seattle Genetics, Abbvie, Chugai Pharma, Regeneron, Nurix, Genmab, Allogene Therapeutics, Lyell Immunopharma Research Funding: Janssen, Novartis, Bristol-Myers Squibb, AstraZeneca, MorphoSys/Incyte, Genentech/Roche, Allogene Therapeutics

In recent months, a growing chorus of legislators has publicly demanded that major banks — including JPMorgan Chase, Deutsche Bank, Bank of America, and Bank of New York Mellon — be held accountable for allegedly facilitating Epstein's sex-trafficking operation through negligent or deliberately under-reported financial activity. A high-profile memorandum released by Ron Wyden (D-Ore.), the top Democrat on the Senate Finance Committee, lays out evidence that JPMorgan severely under-reported “suspicious activity” on Epstein's accounts for years — then suddenly flagged over a billion dollars in transfers only after his 2019 arrest and death. Many lawmakers argue this discrepancy goes beyond careless bookkeeping and points to systemic compliance failures or even criminal complicity, especially given that senior banking executives remained personally involved in Epstein's account oversight.Against this backdrop, Congressional oversight committees have issued subpoenas to banks for financial records tied to Epstein. James Comer, chair of the House Oversight Committee, has demanded full transparency and urged federal prosecutors to open criminal investigations, not only into bank institutions but into individuals who may have knowingly enabled or covered up Epstein's criminal activity. Some lawmakers say that unless those responsible face real consequences — indictments, prosecutions, or heavy penalties — justice for survivors will remain incomplete. There is also growing pressure for regulators to tighten financial-institution oversight and to re-examine how wealthy, high-risk clients are managed by private banking arms.to contact me:bobbycapucci@protonmail.comsource:US regulators ‘taking seriously' allegations of bankers' support for Epstein | Banking | The Guardian

In recent months, a growing chorus of legislators has publicly demanded that major banks — including JPMorgan Chase, Deutsche Bank, Bank of America, and Bank of New York Mellon — be held accountable for allegedly facilitating Epstein's sex-trafficking operation through negligent or deliberately under-reported financial activity. A high-profile memorandum released by Ron Wyden (D-Ore.), the top Democrat on the Senate Finance Committee, lays out evidence that JPMorgan severely under-reported “suspicious activity” on Epstein's accounts for years — then suddenly flagged over a billion dollars in transfers only after his 2019 arrest and death. Many lawmakers argue this discrepancy goes beyond careless bookkeeping and points to systemic compliance failures or even criminal complicity, especially given that senior banking executives remained personally involved in Epstein's account oversight.Against this backdrop, Congressional oversight committees have issued subpoenas to banks for financial records tied to Epstein. James Comer, chair of the House Oversight Committee, has demanded full transparency and urged federal prosecutors to open criminal investigations, not only into bank institutions but into individuals who may have knowingly enabled or covered up Epstein's criminal activity. Some lawmakers say that unless those responsible face real consequences — indictments, prosecutions, or heavy penalties — justice for survivors will remain incomplete. There is also growing pressure for regulators to tighten financial-institution oversight and to re-examine how wealthy, high-risk clients are managed by private banking arms.to contact me:bobbycapucci@protonmail.comsource:US regulators ‘taking seriously' allegations of bankers' support for Epstein | Banking | The GuardianBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

The lawsuits filed against Leon Black in connection with Jeffrey Epstein are among the most graphic and disturbing to emerge from Epstein's orbit. Several women, including Cheri Pierson and a plaintiff identified as Jane Doe, accuse Black of violent sexual assaults that allegedly took place inside Epstein's Manhattan townhouse. Pierson claims Black raped her in 2002 after Epstein arranged what was supposed to be a massage appointment, describing the encounter as brutal and coercive. Another lawsuit alleges Black sexually assaulted a 16-year-old girl with autism and Down syndrome, leaving her bleeding and traumatized. Both cases portray Black as a predator who exploited Epstein's network to target vulnerable women, echoing the broader pattern of abuse associated with Epstein's inner circle. Black's legal team has vehemently denied all allegations, dismissing the claims as false and opportunistic.Compounding the scandal is Black's series of high-dollar settlements and legal maneuvering. In 2023, he quietly paid $62.5 million to the U.S. Virgin Islands to avoid potential litigation tied to Epstein's trafficking operations there. He also succeeded in getting parts of other lawsuits dismissed on procedural grounds, including a defamation case brought by former model Guzel Ganieva, which was thrown out in early 2025. Still, the volume and nature of the claims — combined with his massive financial ties to Epstein and the Senate Finance Committee's scrutiny of his payments — have left Black mired in controversy. The lawsuits' explicit, violent allegations and the perception of systemic leniency have solidified his position as one of the most controversial figures to emerge from Epstein's shadow.to contact me:bobbycapucci@protonmail.com

A new report that links increased alcohol consumption to cancer was supposed to help inform the government's new dietary recommendations. Instead, it hasn't been published. This episode was produced by Rebeca Ibarra, edited by Amina Al-Sadi, fact-checked by Laura Bullard, engineered by Patrick Boyd and Adriene Lilly, and hosted by Sean Rameswaram. Health and Human Services Secretary Robert Kennedy Jr. testifying before the Senate Finance Committee. Photo by Andrew Harnik/Getty Images. Listen to Today, Explained ad-free by becoming a Vox Member: vox.com/members. Transcript at vox.com/today-explained-podcast. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Kate, Leah, and Melissa break down how the lower courts are challenging the Trump administration and expressing their frustration with SCOTUS. Then, they check in with two members of the supermajority: Brett Kavanaugh, who's touting a shiny new shadow docket rebrand, and Amy Coney Barrett as she commences her cursèd book tour. Finally, the hosts speak with Yale Law professor Justin Driver about his book, The Fall of Affirmative Action: Race, the Supreme Court, and the Future of Higher Education.Hosts' and guests' favorite things:Kate: Apologies: You Have Reached the End of Your Free-Trial Period of America! By Alexandra Petri (The Atlantic); Bonus 176: Law, Lawlessness, and Doomerism, Steve Vladeck (One First); How a Top Secret SEAL Team 6 Mission Into North Korea Fell Apart, Dave Philipps and Matthew Cole (NYT)Leah: The DC Circuit's Realpolitik Orders in the Foreign Aid Funding Case, Chris Geidner; 174. Justice Gorsuch's Attack on Lower Courts & Bonus 174: Playing the Justices for Fools, Steve Vladeck (One First); The Supreme Court Is Backing Trump's Power Grab, Kate Shaw & Ezra Klein (NYT).Melissa: RFK's Senate Finance Committee hearing; Hijacking the Kennedys, Reeves Waldman (New York Magazine); Nancy Mace: Everything You Didn't Know About Her Sh*tty Past (Crooked's Hysteria); These Summer Storms, Sarah MacLean; Gwyneth: The Biography, Amy OdellJustin: The Creative Act: A Way of Being, Rick Rubin; Martin Luther King's Constitution: A Legal History of the Montgomery Bus Boycott, Randall Kennedy (Yale Law Journal) Get tickets for STRICT SCRUTINY LIVE – The Bad Decisions Tour 2025! 10/4 – ChicagoLearn more: http://crooked.com/eventsOrder your copy of Leah's book, Lawless: How the Supreme Court Runs on Conservative Grievance, Fringe Theories, and Bad VibesGet tickets to CROOKED CON November 6-7 in Washington, D.C at http://crookedcon.comFollow us on Instagram, Threads, and Bluesky

On this week's DGP Quickie, Julie & Brandy do the dirty deed to the torturous sounds of RFK Jr testifying at the Senate Finance Committee. Like all quickies, it's chaotic and rushed, but Bernie Sanders brings it home for the girls in the end. ******CHECK OUT FREE EPISODES OF JULIE & BRANDY'S PATREON PODCAST******See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

President Donald Trump really, really, really hates wind and solar power. He made sure to make that point very clear during a Cabinet meeting last week, where he ranted about windmills for…way too long. At the end of August, the Trump team ordered construction be stopped on a 4-billion-dollar wind farm project off the coast of Rhode Island that was nearly finished. The administration alluded vaguely to national security threats, suggesting, among other things, that wind farms could be used to launch drone attacks on the U.S. None of this is good. Not just for, you know, preventing the very worst outcomes of climate change that could put billions of lives at risk and alter the very nature of human existence. But also for Americans dealing with spiraling energy bills. So we spoke to Bill McKibben, environmentalist and author of a new book, Here Comes The Sun: A Last Chance for the Climate and a Fresh Chance for Civilization, about climate change, to help us feel more optimistic about the future of the Earth.And in headlines, HHS Secretary Robert F. Kennedy Jr. vs. the Senate Finance Committee, and former Senate Majority Leader Mitch McConnell has some thoughts on how we got here.Show Notes:Check out Bill's new book – wwnorton.com/books/Here-Comes-the-Sun/Call Congress – 202-224-3121Subscribe to the What A Day Newsletter – https://tinyurl.com/3kk4nyz8What A Day – YouTube – https://www.youtube.com/@whatadaypodcastFollow us on Instagram – https://www.instagram.com/crookedmedia/For a transcript of this episode, please visit crooked.com/whataday

John welcomes Puck's chief Washington correspondent, Leigh Ann Caldwell, back to the show to discuss Congress's return to work after its August recess. Leigh Ann assesses the political potency (and limitations) of the public display of solidarity by a phalanx of Jeffrey Epstein survivors in the face of Donald Trump's continued insistence that the story is a “Democrat hoax”; the potential implications of the Senate Finance Committee's bipartisan laceration of RFK, Jr. over his tenure thus far at HHS; and the odds that John Thune and his “pocket rocket” can help avert a government shutdown later this month. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

U.S. warships killed 11 people on a suspected Venezuelan smuggling craft on Tuesday. Secretary of State Marco Rubio suggested they had drugs bound for the U.S., and said Trump planned to “wage war” on drug cartels. Idrees Ali, a Pentagon correspondent for Reuters, has been exploring whether the administration's moves are legal. HHS Secretary Robert F. Kennedy Jr. sparred with Democrats and Republicans on Capitol Hill yesterday in a hearing before the Senate Finance Committee. Stat has the key takeaways. Democrats are looking to regroup and make a plan for the midterms as Congress returns. The Washington Post’s Marianna Sotomayor details the party’s efforts to redefine itself. Plus, Portugal is in mourning after 16 people died in a cable-car tragedy, Trump’s nominee for a role on the Federal Reserve board pledged to be independent, and how to buy Darth Vader’s lightsaber. Today’s episode was hosted by Shumita Basu.

John discusses the sun-baked and hormonally rattled visage of Robert F. Kennedy Jr. who graced the Senate Finance Committee for several hours of back and forth over the Health and Human Services Secretary's new direction for American public health. During his testimony, Kennedy told the committee he had to fire CDC Dir. Susan Monarez because she lied to Americans – unfortunately it wasn't the lies he wanted her to say. Then, he speaks with journalist Brian Karem on the Epstein files, RFK's brain functions, and Trump's waning popularity. Then lastly, John welcomes back the 2 Taras to talk politics. Tara Devlin is a comedian and the host of the Tarabuster, where she looks at news, politics and history through an unapologetically liberal lens. Tara Dublin is a comedian and author of “The Sound of Settling: A Rock & Roll Love Story”. Together Tara Devlin and Tara Dublin are the co-hosts of THE Tara Show podcast. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The sparks flew in Thursday's Senate Finance Committee hearing. Senators – Republicans and Democrats alike – grilled Health and Human Services Secretary Robert F. Kennedy Jr. over his handling of vaccines and the shakeup at the Centers for Disease Control and Prevention. Kennedy, for his part, doubled down on his ouster of CDC director Susan Monarez, claiming she was not “trustworthy.” He insisted that Americans would still be able to access coronavirus vaccines, despite his overhauling of a key vaccine panel. Host Colby Itkowitz speaks with health reporter David Ovalle about the fireworks at Kennedy's hearing before the Senate. Plus, they discuss what's happening with diverging school vaccine policies in red and blue states. Today's show was produced by Elana Gordon with help from Sabby Robinson. It was edited by Peter Bresnan and mixed by Sam Bair. Subscribe to The Washington Post here.

It's Emmajority Report Thursday on Majority Report On today's show: RFK, Jr is grilled at a Senate Finance Committee hearing over the chaos he has created at the CDC. Crypto and Tech Industry researcher and publisher of the Citation Needed newsletter, Molly White joins the show to talk the Trump family crypto cash in. Host of the Colonial Outcasts Podcast, Greg Stoker joins us live from the Global Sumud Flotilla somewhere in the Mediterranean. In the Fun Half Brandon Sutton and Matt Binder join the show. The Congress switchboard number is (202) 224-3121. You can use this number to connect with either the U.S. Senate or the House of Representatives. Become a member at JoinTheMajorityReport.com: https://fans.fm/majority/join Follow us on TikTok here: https://www.tiktok.com/@majorityreportfm Check us out on Twitch here: https://www.twitch.tv/themajorityreport Find our Rumble stream here: https://rumble.com/user/majorityreport Check out our alt YouTube channel here: https://www.youtube.com/majorityreportlive Gift a Majority Report subscription here: https://fans.fm/majority/gift Subscribe to the ESVN YouTube channel here: https://www.youtube.com/esvnshow Subscribe to the AMQuickie newsletter here: https://am-quickie.ghost.io/ Join the Majority Report Discord! https://majoritydiscord.com/ Get all your MR merch at our store: https://shop.majorityreportradio.com/ Get the free Majority Report App!: https://majority.fm/app Go to https://JustCoffee.coop and use coupon code majority to get 10% off your purchase Check out today's sponsors: SHOPIFY: Sign up for a $1/month trial period at shopify.com/majority LIQUID IV: Get 20% off your first order at LIQUIDIV.COM Use code MAJORITYREP at checkout. SMALLS: For a limited time only, get 60% off your first order PLUS shipping when you head to Smalls.com and use code MAJORITY.  SUNSET LAKE:  Head to SunsetLakeCBD.com and buy any three 4-packs, and you'll get a fourth one for free. Just add four 4-packs to your cart and use the code LABORDAY25 at checkout Follow the Majority Report crew on Twitter: @SamSeder @EmmaVigeland @MattLech Check out Matt's show, Left Reckoning, on YouTube, and subscribe on Patreon! https://www.patreon.com/leftreckoning Check out Matt Binder's YouTube channel: https://www.youtube.com/mattbinder Subscribe to Brandon's show The Discourse on Patreon! https://www.patreon.com/ExpandTheDiscourse Check out Ava Raiza's music here! https://avaraiza.bandcamp.com/

The Rich Zeoli Show- Full Episode (09/04/2025): 3:00pm- Will this be the shortest episode of The Rich Zeoli Show ever? Not quite—though, it's only 30-minutes long due to preemption for the Philadelphia Phillies on 1210 WPHT. 3:05pm- On Thursday, Health and Human Services Secretary Robert F. Kennedy Jr. testified before the Senate Finance Committee—answering questions about the Trump Administration's plan to Make America Healthy Again. The hearing resulted in several heated exchanges, most memorably with Sec. Kennedy noting that Sen. Elizabeth Warren has taken nearly $1 million in campaign contributions from pharmaceutical companies. 3:25pm- Malcolm Gladwell reaches his “Tipping Point” with biological males competing in women's sports 3:30pm- Go Eagles! The defending Super Bowl Champion Philadelphia Eagles kickoff their season tonight against the Dallas Cowboys.

RFK Jr.'s testimony in the Senate Finance Committee is a total sh*t show. RFK didn't mention who was president in 2020. RFK didn't know how many Americans died of COVID. West coast states announced healthcare alliance. Tiny Trump blames AI for window tossing video. Florida Surgeon General announces an end to ALL vaccine mandates, including Polio! Epstein Survivors rallied at the Capitol yesterday. Did Donald order military flyovers to disrupt the rally? Is Jim Comer ratf*cking Donald? ADP reports anemic 54,000 jobs added in August. With Jody Hamilton, David Ferguson, music by Powder Pink and Sweet, Mike Farley, and more! Brought to you by Russ Rybicki, AIF®, CRC®, CSRIC™ Socially & Environmentally Responsible Investing: SRIguy.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.